Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Pharmacy Reports Pharmaceutical Sciences and Research (PSR)
Rahmania, Tesia Aisyah
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Chemical Properties, Biological Activities and Poisoning Treatment of Novichok: A Review Rahmania, Tesia Aisyah; Wardhani, Bantari Wisynu Kusuma; Renesteen, Editha; Harahap, Yahdiana
Pharmaceutical Sciences and Research Vol. 8, No. 2
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Novichok is an organophosphate compound found as a nerve agent chemical weapon. However, the information about its chemical properties, biological activities, and molecular interactions in the body are still protected under the “top secret” security clearance. Novichok, with the codes A230, A232 and A234, is a compound whose structure has been successfully determined. The compound is synthesized from a precursor through a nucleophilic substitution reaction. Novichok agents are considered more potent than VX gas and can be applied in unitary and binary forms. This compound has ability for the binding with acetylcholinesterase (AChE) due to inability of acetylcholine metabolism. AChE catalyzes the rapid hydrolysis of acetylcholine to acetate and choline. The treatment of Novichok agent poisoning is similar to management of other nerve agents, such as atropine and pralidoxime administered intravenously. In this paper, we reviewed the Novichok component from chemical and biological perspective. Moreover, we discussed the potential molecular interaction and treatment of this compound.
Potential of pharmacological and herbal for COVID-19: a narrative review Tuba, Syahrul; Rahmania, Tesia Aisyah
Pharmacy Reports Vol. 1 No. 1 (2021): Pharmacy Reports
Publisher : Indonesian Young Scientist Group and UPN Veteran Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (137.051 KB) | DOI: 10.51511/pr.2

Abstract

The pandemic coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs in the prevention and treatment process. At present, there is no proven therapy for this disease, although therapeutic approaches continue to be carried out using traditional medicines (herbal) and pharmacological therapy. Information about SARS-CoV-2 virology has rapidly developed and scientists try to provide a number of potential drugs. Remdesivir has strong in vitro activity against SARS-CoV-2. Several potential drugs are currently underway in a clinical trial. Chloroquine, hydroxychloroquine, and oseltamivir have not been proven to have efficacy, and the benefits of corticosteroids are still diverse. Current clinical evidence does not support the termination of angiotensin-converting enzyme 2 (ACE2) inhibitors or angiotensin receptor blockers, coagulation therapy in patients with COVID-19 concomitant with comorbidities.
Co-Authors Renesteen, Editha Syahrul Tuba Wardhani, Bantari Wisynu Kusuma Yahdiana Harahap